After 10 years of developing leads for clients at BioBlocks, we have created the Leap-to-Lead™ platform to offer improved Lead Discovery outcomes.
September 27 :: Capturing the Data: Improving Patient Outcomes 3:00-5:00pm :: Register Here Could the advancement of new technologies leveraging data and analytics hold the key to transforming healthcare into a more patient centric and cost efficient model? Startups are innovating in areas such as data aggregation, risk stratification, outcomes reporting and even staffing standardization … Continue reading Fall 2017 JLABS San Diego Events
Strategically bolstering the firm’s life sciences capabilities throughout the Northeastern U.S. and globally. Global law firm Hogan Lovells announced today that it will combine with Collora, a Boston-based litigation/investigations firm with a strong focus in life sciences and healthcare, as well as financial services and technology. The combination became effective on September 1st, at which time … Continue reading Hogan Lovells combines with Collora, adding Boston office
Guardant Health CEO, Helmy Eltoukhy and COO, AmirAli Talasaz, join the likes of Mark Zuckerberg, Emmanuel Macron, and Serena Williams on this year’s “40 under 40” Fortune Magazine list. They join other dynamic duos over the years (e.g. Sergey Brin / Larry Page, John Zimmer / Logan Green, and Jerry Yang / David Filo) on the … Continue reading Fortune Magazine – Guardant Health CEO and President on This Year’s “40 under 40” List
The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly “hot” area for pharmaceutical and biotech deal making.
CLSA Member Boehringer Ingelheim expansion will bring nearly 300 new high-wage and highly-skilled positions to the City of Fremont.
Life-sciences ecosystem cuts storage costs by 50 percent, reduces complexity and drastically speeds data analysis of DNA sequencing and interpretation
Researchers to explore development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s gene-correction platform
CLSA President & CEO Sara Radcliffe pens a letter to the editor of The Sacramento Bee, responding to an op-ed by Sen. Ed Hernandez on SB 17, a bill being deceptively sold under the label of drug pricing transparency.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the Los Angeles Daily News outlining the strength of California life sciences industry, and calling on policymakers and stakeholders to sustain and nurture its growth.